HC Wainwright Issues Negative Outlook for iBio Earnings

iBio, Inc. (NASDAQ:IBIO – Free Report) – Research analysts at HC Wainwright cut their Q2 2027 earnings estimates for shares of iBio in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($0.10) per share for the quarter, down from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for iBio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for iBio’s Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.12) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.73) EPS, FY2029 earnings at ($0.65) EPS and FY2030 earnings at ($0.78) EPS.

IBIO has been the subject of a number of other reports. Wall Street Zen raised iBio from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a research report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, iBio has an average rating of “Buy” and an average target price of $6.00.

Read Our Latest Analysis on iBio

iBio Price Performance

Shares of NASDAQ:IBIO opened at $0.85 on Tuesday. iBio has a 12 month low of $0.68 and a 12 month high of $3.82. The stock’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.61.

iBio (NASDAQ:IBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $0.03 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Readystate Asset Management LP purchased a new position in iBio in the 3rd quarter worth about $26,000. R Squared Ltd acquired a new stake in iBio during the 3rd quarter worth about $29,000. Headlands Technologies LLC lifted its stake in iBio by 333.0% during the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after buying an additional 36,463 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in iBio by 15.9% during the first quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company’s stock valued at $893,000 after buying an additional 64,347 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in iBio during the third quarter valued at about $105,000. Institutional investors and hedge funds own 7.90% of the company’s stock.

iBio Company Profile

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Featured Stories

Earnings History and Estimates for iBio (NASDAQ:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.